Did Amarin (AMRN) Just Thread the Needle or is There More NCE Heartache Ahead?
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Jefferies Remains Ultra-Bullish on Amarin (AMRN) Ahead of Commercialization Decision
November 9, 2012 1:54 PM ESTJefferies reiterated its Buy rating and $28 price target on Amarin Corporation (NASDAQ: AMRN) following the company's Q3 update.
"We believe the AMRN story near-term remains driven by a key strategic decision on whether to sell company, partner Vascepa, or launch the drug... More
Amarin Corp Plc (AMRN) Posts Q3 adj.Loss of 26c/Share; Updates on Vascepa Approvals, Exclusivity
November 8, 2012 4:29 PM ESTAmarin Corp Plc (NASDAQ: AMRN) reported Q3 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22).
Vascepa regulatory update
On July 26, 2012, the U.S. Food and Drug Administration (FDA) approved Vascepa (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG >500mg/dL) hypertriglyceridemia. The only reported adverse reaction with an incidence >2% and greater than placebo in Vascepa treated patients was arthralgia (2.3% for Vascepa, 1.0% for placebo). The approved label shows that Vascepa, compared to placebo, reduces TG's, Apo B, non-HDL-C,... More
